Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy

Study limitation reported by the research below: “Only the paper title, DOI, journal, and publication date were provided — no abstract, methods, results, or discussion text was available. All summary content is inferred strictly from the title. Key quantitative outcomes, study design, sample size, population details, and safety data cannot be verified.”